A Clinical Study To Test A Nasal Spray (Fluticasone Furoate Nasal Spray) For The Treatment Of Perennial (Year-round) Allergic Rhinitis

Completed · Phase 4 · Has a placebo group

Conditions studied: Rhinitis, Allergic, Perennial

In brief

The purpose of this study is to compare the effects (effectiveness and safety) of an intranasal corticosteroid (fluticasone furoate nasal spray \[FFNS\]), with a placebo nasal spray for the treatment of perennial (year-round) allergic rhinitis.

Key facts

Study ID

NCT00609674

Run by

GlaxoSmithKline

People needed

315

Starts

2008-01-01

Expected to finish

2008-06-01

Last updated by the study team

2016-12-16

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects eligible for enrollment in the study must meet all of the following criteria:
• Informed consent
• Subject has provided an appropriately signed and dated informed consent.
• An appropriately signed and dated assent must be obtained from the parents or guardian if the subject is a child under 18 years of age.
• Outpatient
• Subject is treatable on an outpatient basis.
• Age
• ≥ 12 years at Visit 2
• ≥ 18 years at Visit 1 for Russia and Germany
• Male or eligible female. Female subjects should not be enrolled if they plan to become pregnant during the time of study participation. A urine pregnancy test will be performed for all females of childbearing potential at Visits 1, 2, 5, and Visit 6/Early Withdrawal to determine if the subject is pregnant.
• To be eligible for entry into the study, females of childbearing potential must commit to the consistent and correct use of an acceptable method of birth control, as defined by the following:
• Abstinence Females of childbearing potential who are not sexually active must commit to complete abstinence from intercourse for two weeks before exposure to the study drug, throughout the clinical trial, and for a period after the trial to account for elimination of the drug (minimum of six days).
• Oral contraceptive (either combined estrogen/progestin or progestin only),
• Injectable progestogen,
• Implants of levonorgestrel,
• Percutaneous contraceptive patches,
• Intrauterine device (IUD) or intrauterine system (IUS) with a documented failure rate of less than 1% per year,
• Male partner who is sterile (vasectomy with documentation of azospermia) prior to the female subject's entry into the study and is the sole sexual partner for that female subject,
• Double barrier method-condom or occlusive cap (diaphragm or cervical /vault caps) plus spermicide,
• Estrogenic vaginal ring
• Diagnosis of PAR to include:
• A positive skin test (by prick method) response to appropriate perennial allergen (house dust mites, animal dander, mold, or cockroach) within last 12 months prior to Visit 1 or at Visit 1.
• A positive skin test is defined as a wheal ≥3mm larger than the diluent control for prick testing.
• Two year medical history and past treatment of PAR (written or verbal confirmation) which includes perennial, i.e., year-round, symptoms. PAR symptoms would include nasal congestion, rhinorrhea, nasal itching and sneezing, eye itching/burning, eye tearing/watering, and eye redness.
• In vitro tests for specific IgE (such as RAST, PRIST) will not be allowed for the diagnosis of PAR.

You may not qualify if…

• Subjects meeting any of the following criteria must not be enrolled in the study:
• Significant concomitant medical conditions, defined as but not limited to:
• a historical or current evidence of clinically significant uncontrolled disease of any body system (e.g., tuberculosis, psychological disorders, eczema). Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through study participation or which would confound the interpretation of the study results if the disease/condition exacerbated during the study.
• a severe physical obstruction of the nose (e.g., deviated septum or nasal polyp) or nasal septal perforation that could affect the deposition of double blind intranasal study drug
• nasal (e.g., nasal septum) or ocular injury/surgery in the last 3 months
• asthma, with the exception of mild intermittent asthma [NAEPP, 2007; GINA, 2006], or very mild asthma (Canada) [Lemiére, 2004].
• NOTE: Subjects will be allowed to use short-acting inhaled beta2 agonists ONLY on an as needed basis.
• rhinitis medicamentosa
• bacterial or viral infection (e.g., common cold) of the eyes or upper respiratory tract within two weeks of Visit 1 or during the screening period
• documented evidence of acute or significant chronic sinusitis, as determined by the individual investigator
• current or history of glaucoma and/or ocular herpes simplex
• current cataract
• physical impairment that would affect subject's ability to participate safely and fully in the study
• clinical evidence of a Candida infection of the nose
• history of psychiatric disease, intellectual deficiency, poor motivation, substance abuse (including drug and alcohol) or other conditions that will limit the validity of informed consent or that would confound the interpretation of the study results
• history of adrenal insufficiency
• Use of corticosteroids, defined as:
• Intranasal corticosteroid within 4 weeks prior to Visit 1 (e.g., FLONASE™, VERAMYST, Nasonex, Rhinocort).
• Inhaled, oral, intramuscular, intravenous, ocular, and/or dermatological corticosteroid (with the exception of hydrocortisone cream/ointment, 1% or less, or equivalent) within 8 weeks prior to Visit 1.
• Use of other allergy medications within the timeframe indicated relative to Visit 1
• Intranasal or ocular cromolyn within 14 days prior to Visit 1 (e.g., Nasalcrom, Crolom)
• Short-acting prescription and non-prescription antihistamines, including ocular preparations and antihistamines contained in insomnia and "night time" pain formulations, within 3 days prior to Visit 1 (e.g., Benadryl, Chlortrimeton, Dimetane, Tavist)
• Long-acting antihistamines within 10 days prior to Visit 1, including loratadine, desloratadine, fexofenadine, cetirizine, levocetirizine, terfenadine (e.g., Allegra, Claritin, Clarinex, Zyrtec)
• Long-acting antihistamine, astemizole, within 12 weeks prior to Visit 1
• Intranasal antihistamines (e.g., Astelin) within 2 weeks prior to Visit 1

Where it is running

• GSK Investigational Site — Providence, Rhode Island, United States
• GSK Investigational Site — South Burlington, Vermont, United States
• GSK Investigational Site — Greenfield, Wisconsin, United States
• GSK Investigational Site — Winnipeg, Manitoba, Canada
• GSK Investigational Site — St. John's, Newfoundland and Labrador, Canada
• GSK Investigational Site — Hamilton, Ontario, Canada
• GSK Investigational Site — Kanata, Ontario, Canada
• GSK Investigational Site — Mississauga, Ontario, Canada
• GSK Investigational Site — Ottawa, Ontario, Canada
• GSK Investigational Site — Toronto, Ontario, Canada
• GSK Investigational Site — Québec, Quebec, Canada
• GSK Investigational Site — Trois-Rivières, Quebec, Canada
• GSK Investigational Site — Saskatoon, Saskatchewan, Canada
• GSK Investigational Site — Tallinn, Estonia
• GSK Investigational Site — Tartu, Estonia
• GSK Investigational Site — Hanover, Lower Saxony, Germany
• GSK Investigational Site — Magdeburg, Saxony-Anhalt, Germany
• GSK Investigational Site — Berlin, State of Berlin, Germany
• GSK Investigational Site — Budapest, Hungary
• GSK Investigational Site — Budapest, Hungary
• GSK Investigational Site — Budapest, Hungary
• GSK Investigational Site — Budapest, Hungary
• GSK Investigational Site — Moscow, Russia
• GSK Investigational Site — Moscow, Russia
• GSK Investigational Site — Saint Petersburg, Russia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.